FDA's Makary pledges a crackdown on mass compounded GLP-1 marketing
Posted by weekendnate in Research & News - 1 points, 4 comments.
Fierce Pharma has FDA commissioner Makary coming out hard against mass marketing of compounded GLP-1 copycats, and the timing is not subtle. Hims just announced a $49 compounded Wegovy pill and within hours the FDA is signaling enforcement. Good. The whole "personalized compounding" exemption was never meant to be a backdoor wholesale channel, and pretending otherwise just trains people to skip the actual medical piece.
My concern is the letter of the law versus the practical effect. If the FDA squeezes the big compounders, the people who actually benefited from $200 tirz versus $1100 brand are going to get priced right back out. I saw this pattern play out with my own run, and a lot of folks are going to be stuck mid-protocol.
Is the answer tighter enforcement, or just getting generics approved faster so this whole gray market collapses on its own?
Comments
- elle_z: Yeah this one hits close to home 😅 I went through my own tirz run earlier this year and the price difference was kind of the whole reason it was doable for me. If the big compounders get squeezed and there's nothing to catch the fall, a lot of people mid protocol are basically stuck. Either keep paying brand prices or just stop cold, neither is great. I think the generics path is the real answer but lol good luck waiting on that, the FDA moves at its own pace. Enforcement feels more like vibes
- weekendnate: Honestly I think you're right that enforcement alone is vibes without a cheaper option waiting. The patent litigation timeline is the real bottleneck, not the FDA's willingness to approve generics. That's exactly my worry. People in month 6 of a protocol don't get to pause and wait for Sandoz or whoever to sort out supply chains. And cold stopping isn't benign either, the rebound appetite hits hard and a lot of people gain it all back within a couple months. Curious what your run looked like f
- biohacker_priya: Yeah, that part worries me too. The compounding loophole gave a lot of people access they genuinely couldn't afford otherwise, and if enforcement just closes the door without a cheaper FDA-approved option ready to go, what was the point. Generic semaglucane can't come fast enough...
- weekendnate: They spelled it semaglucane, which is the kind of thing that makes me trust their post less. The access point is real though. When I was on tirz last year I paid $240 from a mid-tier pharmacy, and brand was $1100+ at the same time. That gap is the whole story for most people who actually use these. Tighter enforcement without a generic landing is a bad combo. You just push folks to sketchy grey-market sites or overseas pharmacies where nobody is checking sterility. The Hims pricing is a bandaid
Community discussion - research and educational context only. Not medical advice.